Interestingly, in patients with inflammatory bowel disease and anti-TNF-α therapy the increase in Th17 and IL-17A levels indicates a better outcome, while the opposite is observed in MS patients, who worsen as IL-17 increases under TNF-α blockade (33–35). Here, IL17A is linked to myeloid sarcoma.